RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB1 day ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
Recordati buys rights to rare immune disorder drug from ...
WEB22 hours ago · Recordati said it had signed an agreement for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA).
Sanofi Offloads Rare Autoimmune Drug to Recordati in ...
WEB15 hours ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 ...
WEB21 hours ago · Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB22 hours ago · Recordati (REC.MI) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB22 hours ago · Eugenia Litz +44 7824 394 750 investorelations@recordati.it. Gianluca Saletta +39 348 979 4876 investorelations@recordati.it. Media Relations. ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected]. UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 recordati@consilium-comms.com
Italian pharma company Recordati makes an acquisition ... - STAT
WEB16 hours ago · Italian pharma company Recordati said it will buy from Sanofi the global rights to an approved drug to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million, Reuters reports ...
Italy's Recordati hikes 2024 guidance after core profit rises ...
WEBJul 30, 2024 · Italian drug maker Recordati raised its guidance for 2024 on Tuesday buoyed by positive momentum in its mainline Specialty and Primary Care and Rare Disease segments and an 11.5% rise in...
Recordati shares rise as investors reportedly circle CVC stake
WEBJun 18, 2024 · Shares in Italian drugmaker Recordati rose almost 3% on Tuesday, boosted by a report that investment funds KKR and TPG had expressed preliminary interest in buying a stake in the company.
CVC Explores Options for €11 Billion Drugmaker Recordati
WEBApr 23, 2024 · CVC Capital Partners is exploring options for its controlling stake in Italian drugmaker Recordati SpA, according to people familiar with the matter.